Haemophagocytic lymphohistiocytosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 0
• BRAF 0
• MEK 0
• CD22 0
• BCMA 0
• CD20 0
• JAK 0
• PSMA 0
• TNF 0
• ALK 0
• AQP4 0
• BRCA1 0
• GPRC5D 0
• STING 0

24 of 277 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Immunobiology of malignancy-associated hemophagocytic lymphohistiocytosis

  University of Pennsylvania· Philadelphia, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• NIH NIAID · R21

  Targeting Runx3 as a Novel Treatment for Hemophagocytic Lymphohistiocytosis

  University of Texas Hlth Ctr at Tyler· Tyler, United States· US$223,500 awarded in fiscal year 2026· until Jun 2028

• NIH NIGMS · R01

  Mechanisms of Lytic Granules Exocytosis

  Thomas Jefferson University· Philadelphia, United States· US$567,411 awarded in fiscal year 2026· until Jan 2030

• NIH NIAID · K08

  Cellular mechanisms of macrophage activation syndrome

  University of Washington· Seattle, United States· US$187,692 awarded in fiscal year 2026· until May 2030

• NIH NIAMS · R01

  Pathogenesis of Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease

  Cincinnati Childrens Hosp Med Ctr· Cincinnati, United States· US$474,257 awarded in fiscal year 2026· until Feb 2027

5 of 8 running projects, newest first. Listed amounts together: US$5.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Pre-emptive Anakinra for Cytokine Event Reduction

  NCT06703216· Kevin McNerney· Updated 13 Aug 2026

  “The trial has been stopped pending FDA approval of modifications to the trial protocol.”Registry text, quoted unchanged. Source

• Terminated

  Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

  NCT02780583· University of Alabama at Birmingham· Updated 1 Aug 2024

  “no further funding to continue, investigator relocated, no replacement found to continue”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

  NCT06339177· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer

  NCT03827343· National Cancer Institute (NCI)· Source

• Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

  NCT06160791· Jerry Lee, MD, MSc, MPhil· Source

• All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis

  NCT07626398· Beijing Anzhen Hospital· Source

• Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

  NCT04551131· St. Jude Children's Research Hospital· Source

• Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis

  NCT07531069· Fudan University· Source

• INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)

  NCT05277272· Children's Hospital Medical Center, Cincinnati· Source

• Anakinra in Dengue With Hyperinflammation ( AnaDen )

  NCT05611710· Oxford University Clinical Research Unit, Vietnam· Source

• The Microbiome in Blood Cancer and HLH

  NCT06734624· University of Nottingham· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• CRISPR-Cas Systems 2
• Gene Expression Profiling 3
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 2
• Flow Cytometry 6
• Immunohistochemistry 1
• Magnetic Resonance Imaging 11
• Machine Learning 6
• Deep Learning 1
• Cohort Studies 5

See which targets of this disease your abstract mentions, and go to the people working on them.